SecBot SecBot
8-K ·Filed Nov 9, 2026

LSTA

LISATA THERAPEUTICS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed12d 14h ago SEC0001140361-26-042818
8-K context-dependent: Items 5.02, 8.01
Actionable Insight • Neutral

The key event to watch is the reconvened meeting on November 30, 2026 for the Series C conversion proposal. If approved, the conversion would issue shares representing >20% of outstanding common stock and trigger a change of control, which would be highly dilutive. Monitor the outcome and any Nasdaq listing application decision.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$1.02
T+0 close · Nov 9, 2026 · via day close
Latest settled
+1.96%
T+5 · $1.04 · next T+20 in 17d
Vs SPY
+4.29%
α at T+5
Latest observation
−12.23%
T+8 · FF3 residual α
  1. T+0 · Nov 10 $1.02entry
  2. T+1 · 11d ago +17.65%α +16.33% · $1.20
  3. T+5 · 5d ago +1.96%α +4.29% · $1.04
  4. T+8 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lisata Therapeutics held its 2026 annual meeting on November 9, 2026. Stockholders approved the 2026 Equity Incentive Plan (44,764,472 initial shares plus annual evergreen increases) and the 2026 Employee Stock Purchase Plan (3,730,372 initial shares). The meeting was adjourned solely on Proposal No. 3 (conversion of Series C Convertible Preferred Stock, which would represent >20% of outstanding shares and result in a change of control) to allow more time for proxy solicitation and Nasdaq listing application approval; the reconvened meeting is set for November 30, 2026.

Key Facts

  • Stockholders approved the 2026 Equity Incentive Plan with an initial reserve of 44,764,472 shares plus annual evergreen increases of 5% of outstanding shares.
  • Stockholders approved the 2026 Employee Stock Purchase Plan with an initial reserve of 3,730,372 shares plus annual evergreen increases through 2036.
  • The annual meeting was adjourned solely on Proposal No. 3 (conversion of Series C Non-Voting Convertible Preferred Stock) to allow more time for proxy solicitation and Nasdaq listing application approval.
  • The reconvened meeting on Proposal No. 3 is scheduled for November 30, 2026.
  • All director nominees (Cynthia L. Flowers and Dr. Ted W. Love) were elected.
  • Stockholders approved a reverse stock split authorization (range 1-for-5 to 1-for-15).
  • Say-on-pay advisory vote passed with 3,426,250 for, 975,321 against, 267,353 abstained.
  • 10,804,066 shares outstanding as of record date; 8,172,668 shares (75.64%) present at the meeting.

Financial Impact

No immediate financial impact. The 2026 equity plans authorize significant potential dilution (44.8M shares for the equity plan, 3.7M for the ESPP, plus annual evergreen increases) but no grants have been disclosed. The pending conversion of Series C preferred stock would represent >20% of outstanding shares and result in a change of control, but the vote was adjourned.

dilutionshare count

Risk Factors

  • Pending conversion of Series C preferred stock could result in massive dilution (>20% of outstanding shares) and a change of control if approved at the reconvened meeting.
  • The company's market cap is only $11M, making the potential dilution from the 44.8M share equity plan and 3.7M share ESPP extremely significant relative to current market value.
  • Reverse stock split authorization (1-for-5 to 1-for-15) signals potential Nasdaq compliance concerns.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-042818
Document: ef20085190_8k.htm0001140361-26-042818
Document: ef20085190_ex10-2.htm0001140361-26-042818
Document: 0001140361-26-042818-index-headers.html0001140361-26-042818
Document: 0001140361-26-042818-index.html0001140361-26-042818
Document: 0001140361-26-042818.txt0001140361-26-042818

Track record

21 reports on LSTA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +54.62% at T+60 after the Jun 9, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 19, 20262d ago S-3/A Bearish 6/10 Entry $0.9507 settles Feb 19
  2. Nov 19, 20262d ago 8-K/A Neutral 3/10 Entry $0.9507 settles Feb 19
  3. Nov 19, 20262d ago 8-K Bearish 5/10 Entry $0.9100 settles Feb 18
  4. Nov 19, 20262d ago Press Release Neutral 4/10 Entry $0.9100 settles Feb 18
  5. Nov 12, 20269d ago S-3 Bearish 6/10 Entry $1.21 settles Feb 11
  6. Nov 12, 202610d ago 8-K/A Neutral 4/10 Entry $1.28 settles Feb 10
  7. Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $1.02 settles Feb 8
  8. Nov 9, 202612d ago 8-K Neutral 4/10 Viewing Entry $1.02 settles Feb 8
  9. Oct 19, 20264w ago DEF 14A Bearish 7/10 Entry $1.00 settles Jan 14
  10. Oct 14, 20265w ago 8-K Neutral 2/10 Entry $1.07 settles Jan 12
Showing 10 of 21

US Market Status

Market Closed · Opens Mon (26h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026